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Abstract: Mitotane is the main option of treatment for advanced adrenocortical carcinoma (ACC).
However, limited evidence is available regarding the impact of plasma mitotane levels on patient
outcome. To address this question, we retrospectively analyzed patients with advanced ACC treated
with mitotane for ≥3 months, with ≥3 measurements of plasma mitotane reported in the Lysosafe
Online® database (HRA Pharma, France), followed at 12 tertiary centers in Italy from 2005 to 2017.
We identified 80 patients, initially treated with mitotane alone (56.2%) or plus chemotherapy (43.8%).
The preference toward combination therapy was given to de novo stage IV ACC and younger patients.
After the first line of treatment, 25% of valid cases experienced clinical benefit (14.5% objective
response, 10.5% stabilization of disease) and 75% progression, without differences between the groups
of treatment. Patients with progression had a lower time in the target range (TTR) of plasma mitotane
and an unfavorable outcome. Death occurred in 76.2% of cases and multivariate analysis showed that
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clinical benefit after first treatment and longer TTR were favorable predictors of overall survival (OS).
In conclusion, the present findings support the importance of mitotane monitoring and strengthen
the concept of a therapeutic window for mitotane.
Keywords: adrenal cancer; mitotane; prognosis; recurrence; survival
1. Introduction
The last years have witnessed an unprecedented development in medical oncology, with the
introduction in clinics of targeted drugs and immune therapies that changed the prognosis of several
cancers. This advancement has not included medical therapy of adrenocortical carcinoma (ACC),
which remains based on a drug that has been developed in the sixties, mitotane.
Mitotane is approved by US and European regulatory agencies for treatment of advanced ACC,
albeit being increasingly used in the adjuvant setting also [1]. The European Society of Endocrinology
and the European Network for the Study of Adrenal Tumors (ESE-ENSAT) guidelines on management
of ACC suggest mitotane monotherapy for patients harboring advanced ACC with favorable prognostic
parameters, while mitotane associated with chemotherapy is indicated in patients with perceived
worse prognosis (i.e., aggressive tumors) [2]. This indication has a limited evidence base, since only
one randomized controlled study is available on the association of mitotane with chemotherapy in
advanced ACC [3].
Therefore, we thought it of interest to do a survey on the use of mitotane as treatment of advanced
ACC not amenable to surgical resection in referral centers for ACC care in Italy. The study aim was to
assess whether mitotane levels impact on the response to treatment and patient outcome. Studies have
shown the therapeutic value of mitotane concentrations is 14–20 mg/L; however, the validation of this
range was done using the peak mitotane level [4–6], which cannot give an adequate representation
of a chronic exposure to mitotane, being a measurement at a single point in time, or the percentage
of mitotane measurements in a range [7,8], which is strongly dependent on the number of available
measurements. To get a better assessment of the exposure to mitotane over time, we assessed the
time in target range (TTR), defined as the number of months in which mitotane concentrations were
≥14 mg/L. The TTR has been introduced for assessing the optimal exposure to warfarin therapy [9],
and since there is an analogy between mitotane and warfarin concerning the need to get drug levels
within a defined range of concentrations, we evaluated whether the TTR may influence patient survival.
2. Results
From a total of 241 patients with advanced ACC on the Lysosafe® Online database, 80 patients
fulfilled inclusion/exclusion criteria and were retrospectively included in the study (Figure 1). Baseline
characteristics of the patients are reported in Table 1.Cancers 2020, 12, 740 3 of 12 
 
Figure 1. Study cohort. 
Table 1. Baseline features of patients. 
Characteristics Valid Cases (N) Values 
Gender, N (%) 80  
Male  25 (31.2%) 
Female  55 (68.8%) 
Age at diagnosis, year 80  
Median (IQR)  50 (36–59) 
Tumor stage at diagnosis, N (%) 80  
Stage I  3 (3.7%) 
Stage II  28 (35%) 
Stage III  18 (22.5%) 
Stage IV  31 (38.8%) 
Hormone secretion at diagnosis, N (%) 77  
Yes  51 (66.2%) 
No  26 (33.8%) 
Weiss score 51  
Median (IQR)  6 (5–7) 
Ki67 55  
Median (IQR)  25 (13–38) 
≤10%  14 (25.5%) 
>10%  41 (74.5%) 
Hormone secretion at start of palliative 
treatment, N (%) 
77  
Yes  25 (32.5%) 
No  52 (67.5%) 
ENSAT tumor stage at start of palliative 
treatment, N (%) 
80  
Stage I  0 (0%) 
Stage II  0 (0%) 
Stage III  7 (8.7%) 
Stage IV  73 (91.3%) 
Number of metastatic organs   78  
Median (IQR)  2 (1–2) 
1 organ, N (%)  29 (37.2%) 
2 organs, N (%)  34 (43.6%) 
3 organs, N (%)  10 (12.8%) 
 4 organs, N (%)  5 (6.4%) 
Organ/system involved   78  
Lungs  47 (60.3%) 
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Table 1. Baseline features of patients.
Characteristics Valid Cases (N) Values
Gender, N (%) 80
Male 25 (31.2%)
Female 55 (68.8%)
Age at diagnosis, year 80
Median (IQR) 50 (36–59)
Tumor stage at diagnosis, N (%) 80
Stage I 3 (3.7%)
Stage II 28 (35%)
Stage III 18 (22.5%)
Stage IV 31 (38.8%)
Hormone secretion at diagnosis, N (%) 77
Yes 51 (66.2%)
No 26 (33.8%)
Weiss score 51
Median (IQR) 6 (5–7)
Ki67 55
Median (IQR) 25 (13–38)
≤10% 14 (25.5%)
>10% 41 (74.5%)
Hormone secretion at start of palliative
treatment, N (%) 77
Yes 25 (32.5%)
No 52 (67.5%)
ENSAT tumor stage at start of palliative
treatment, N (%) 80
Stage I 0 (0%)
Stage II 0 (0%)
Stage III 7 (8.7%)
Stage IV 73 (91.3%)
Number of metastatic organs 78
Median (IQR) 2 (1–2)
1 organ, N (%) 29 (37.2%)
2 organs, N (%) 34 (43.6%)
3 organs, N (%) 10 (12.8%)
≥ 4 organs, N (%) 5 (6.4%)
Organ/system involved 78
Lungs 47 (60.3%)
Liver 37 (47.4%)
Lymphatic system 15 (49.2%)
Local site (vena cava, adrenal loggia) 13 (16.7%)
Peritoneum and retroperitoneum 8 (10.3%)
Kidney 8 (10.3%)
Skeletal system 7 (9.0%)
Spleen 3 (3.8%)
Abdominal muscles (psoas, diaphragm) 3 (3.8%)
Colon 2 (2.6%)
IQR = interquartile range. N = number of patients.
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The median follow-up was 33 (22–51.2) months. Twenty-four patients were previously treated
with adjuvant mitotane before ACC recurrence while 56 patients started mitotane (±chemotherapy) as
first-line medical treatment of ACC recurrence or advanced disease at diagnosis. Median duration
of palliative treatment was 33 (22–49) months, with a median of 8 (5–12) measurements of plasma
mitotane concentration and a median time interval between two consecutive measurements of 2 (1–3)
months. At the end of the follow-up, 14 patients (17.5%) were still on mitotane therapy, after a
median of 67 (43–102) months of palliative mitotane treatment, and 48 (72.7%) were treated until death,
with a median duration of 31 (21–44) months. Other causes of treatment discontinuation were ACC
progression (n = 10), unknown (n = 5), or patient’s decision (n = 3).
In the overall group, the achievement of target mitotane levels required a median time of 6 (3–9)
months from the start of therapy while 14 patients (17.5%) never achieved levels ≥ 14 mg/L. The peak
of plasma mitotane concentrations was 20.8 (14.8–25.0) mg/L, which was reached after a median of 11
(6–20) months.
Forty-five patients (56.2%) were initially treated only with mitotane (4 of which received
concomitant local radiotherapy) while 35 (43.8%) were treated with a combination of chemotherapy
and mitotane, in most cases with the EDP-M (etoposide, doxorubicin, and cisplatin, plus mitotane)
regimen (Figure 2).
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Figure 2. Management of advanced adrenocortical carcinoma (ACC)in our series. * 17 patients were 
previously on adjuvant mitotane. § 7 patients were previously on adjuvant mitotane. EDP = etoposide, 
doxorubicin and cisplatin. EP = etoposide and cisplatin. P = cisplatin. 
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The comparison between the baseline characteristics of these two groups showed that patients
treated with the combination of chemotherapy and mitotane were younger (43, 33–58 years, vs. 54,
45–62 years; p = 0.036) and with worse presentation at diagnosis (de novo ENSAT stage IV, 57.1% vs.
24.4%; p = 0.012) (Table 2).
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Table 2. Comparison between patients starting palliative treatment with mitotane monotherapy vs.
patients starting with the association mitotane + chemotherapy.
Characteristics Mitotane MonotherapyN◦ 45
Mitotane + Chemotherapy
N◦ 35 p Value
Gender, (valid cases) (45) (35) 0.43
Male, N (%) 12 (26.7) 13 (37.1)
Female, N (%) 33 (73.3) 22 (62.9)
Age at time of palliative
treatment, year
(valid cases) (45) (35) 0.036
Median (IQR) 54 (45–62) 43 (33–58)
Hormone secretion at start of
palliative treatment
(valid cases) (42) (31) 0.085
Yes, N (%) 9 (21.4) 14 (45.2)
No, N (%) 33 (78.6) 17 (54.8)
Number of metastatic organs
(valid cases)
(43) (35) 0.92
≤ 2 organs, N (%) 35 (81.4) 28 (80)
> 2 organs, N (%) 8 (18.6) 7 (20)
De novo stage IV *
(valid cases) (45) (35) 0.012
N (%) 11 (24.4) 20 (57.1)
Previous adjuvant therapy
(valid cases) (45) (35) 0.17
Yes, N (%) 17 (37.8) 7 (20)
No, N (%) 28 (62.2) 28 (80)
Previous RFS
(valid cases) (18) (7) 0.74
Median (IQR) 16 (6–26) 16 (5–54)
* De novo stage IV means that patients were diagnosed with stage IV ACC. IQR = interquartile range. N = number
of patients. RFS = recurrence free survival. Statistically significant outcomes are presented in bold.
During the entire period of follow-up, 12 patients were treated only with mitotane while the
remaining 68 received mitotane in combination with one or more chemotherapy treatments (in 61 cases,
at least one regimen including platinum compound).
The comparison between the baseline characteristics of these two groups showed that patients
treated with multiple lines of treatment were younger than those treated with mitotane only (48.5,
35–58.2 years, vs. 58.5, 52.7–69.2 years; p = 0.023) (Table 3). We found that patients treated only
with mitotane achieved a higher peak of mitotane concentrations (26.4, 21.7–29.2 mg/L, vs. 19.2,
14.7–24.6 mg/L, p = 0.028) and had a more favorable outcome (6/12 (50%) vs. 13/55 (23.6%) patients
alive at last follow-up, p = 0.022).
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Table 3. Comparison between patients treated with mitotane monotherapy during all follow-up vs.
patients treated with different lines of treatment.
Characteristics Mitotane MonotherapyN◦ 12
Mitotane + Chemotherapy
N◦ 68 p Value
Gender, (valid cases) (12) (68) 0.90
Male, N (%) 4 (33.3%) 21 (30.9%)
Female, N (%) 8 (66.6%) 47 (69.1%)
Age at time of palliative
treatment, year
(valid cases) (12) (68) 0.023
Median (IQR) 58.5 (52.7–69.2) 48.5 (35–58.2)
Hormone secretion at start of
palliative treatment
(valid cases) (11) (62) 0.80
Yes, N (%) 3 (27.3) 20 (32.3)
No, N (%) 8 (72.7) 42 (67.7)
Number of metastatic organs
(valid cases)
(11) (67) 0.95
≤ 2 organs, N (%) 9 (81.8) 54 (80.6)
> 2 organs, N (%) 2 (18.2) 13 (19.4)
De novo stage IV
(valid cases) (12) (68) 0.85
N (%) 5 (41.7) 26 (38.2)
Previous adjuvant therapy
(valid cases) (12) (68) 0.75
Yes, N (%) 3 (25) 21 (30.9)
No, N (%) 9 (75) 47 (69.1)
Previous RFS
(valid cases) (3) (22) 0.18
Median (IQR) 27 (23–39) 13 (5–26)
* De novo stage IV means that patients were diagnosed with stage IV ACC. IQR = interquartile range. N = number
of patients. RFS = recurrence free survival. Statistically significant outcomes are presented in bold.
Considering the first line of treatment, 19 patients (23.7%) experienced clinical benefit (10 out of
35 (28.6%) patients treated with mitotane + chemotherapy and 9 out of 45 (20%) patients in mitotane
monotherapy), of whom 11 (57.9%) had an objective response (8 partial, 3 complete) and 8 (42.1%) had
stabilization of disease, while the remaining 57 (71.2%) had progression (24 out of 35 (68.6%) patients
treated with mitotane + chemotherapy and 33 out of 45 (73.3%) patients in mitotane monotherapy),
according to the RECIST 1.1 criteria [10] (data not available for 4 patients).
The comparison between the baseline characteristics of these two groups is given in Table 4.
We found that patients with ACC progression had a lower TTR (8.6, 0.8–14.1 months, vs. 15.8,
2.7–32.7 months; p = 0.033) and an unfavorable outcome (7/57 patients (12.3%) vs. 12/19 (63.2%) patients
alive at last follow-up, p = 0.022).
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Table 4. Comparison between patients who had clinical benefit vs. patients who progressed at the first
line of treatment.
Characteristics Clinical BenefitN◦ 19
Progression
N◦ 57 p value
Gender, (valid cases) (19) (57) 1.00
Male, N (%) 6 (31.6%) 18 (31.6%)
Female, N (%) 13 (68.4%) 39 (68.4%)
Age at time of palliative
treatment, year
(valid cases) (19) (57) 0.17
Median (IQR) 50 (35.5–56) 51 (38–64)
Hormone secretion at start of
palliative treatment
(valid cases) (19) (51) 0.36
Yes, N (%) 4 (21.1) 18 (35.3)
No, N (%) 15 (78.9) 33 (64.7)
Number of metastatic organs
(valid cases) (19) (56) 0.72
≤ 2 organs, N (%) 16 (84.2) 44 (78.6)
> 2 organs, N (%) 3 (15.8) 12 (21.4)
De novo stage IV
(valid cases) (19) (57) 0.17
N (%) 10 (52.6) 18 (31.6)
Previous adjuvant therapy
(valid cases) (19) (57) 0.74
Yes, N (%) 4 (26.3) 18 (31.6)
No, N (%) 14 (73.7) 39 (68.4)
* De novo stage IV means that patients were diagnosed with stage IV ACC. IQR = interquartile range. N = number
of patients.
Considering the entire cohort of patients, death occurred in 61 cases (76.2%). Median overall
survival (OS) was 35 months (CI95%, 31–49). Multivariate analysis showed that clinical benefit after
the first-line treatment and the TTR were independent predictors of OS (Table 5).
Table 5. Multivariate analysis with significant predictors of OS.
Tumor Response §
HR CI 95% p
0.387 0.173 0.869 0.021
TTR * 0.484 0.308 0.759 0.002
§ Reference category: clinical benefit vs progression. * HR is computed on a difference of 15 months. TTR = time in
target range. HR = hazard ratio. CI = confidence interval.
3. Discussion
Management of patients with advanced ACC also remains a challenge in referral centers. ACC
may present with metastatic disease at diagnosis in about one quarter of cases, or progress to advanced
disease after an initial apparently complete resection [11,12]. The prognosis of advanced ACC is
generally poor when surgery is unfeasible, with a reported 5-year survival less than 15% [11,13].
Our study shows that less than a quarter of patients were alive after 3 years of follow-up, with
a median survival of 35 months. These data confirm the high mortality of advanced ACC [12,14];
however, they also follow the trend of a better prognosis observed in the most recent studies [13]. The
present study shows that the lung is the organ most commonly involved by metastatic spread, with a
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higher frequency than previously reported in clinical series [14] but with a similar rate of autoptic [15]
or surgical series [16,17]. The disease burden in our cohort was remarkable, with the presence of
≥two organs involved in about two thirds of cases, and also hormone secretion was found in a similar
percentage of cases at diagnosis. It is worth noting that a remarkable number of secreting tumors at
diagnosis recurred as not secreting tumors (secreting tumors 66.2% at diagnosis vs. 32.5% at the start
of palliative treatment). The patient cohort enrolled in the FIRMACT study had quite a higher tumor
burden and less secreting tumors, and this difference likely results from the specific inclusion criteria
of that study (all patients were treated with chemotherapy in addition to mitotane) [3].
The present study reports on the current practice in the management of advanced ACC, either
stage IV at diagnosis or recurrent ACC following initial surgery, focusing on the first-line treatment.
It is generally agreed that the two major options are mitotane monotherapy or mitotane combined
with chemotherapy, with a regimen including platinum compounds [12,14]. The choice depends on
patient conditions, tumor characteristics, and center preference. The standard chemotherapy regimen
is EDP-M, introduced by a multicenter prospective phase II study carried out in Italy [18,19] and
validated in a worldwide prospective randomized phase III clinical trial [3]. Our series demonstrated
that this finding has been implemented in current practice, since EDP was the regimen of choice as the
first treatment in most of our patients. In some cases, the parent regimens EP, or cisplatin monotherapy,
were used due to limited toxicity. Conversely, the combination of streptozotocyn and mitotane was
employed in less than 10% of cases.
In our cohort, the two options (mitotane alone or plus chemotherapy) were almost equally chosen;
however, preference toward mitotane combined with chemotherapy was given to de novo stage IV
ACC and younger patients. This choice likely reflects the perception that a metastatic presentation at
diagnosis implies an aggressive ACC and that younger patients are fit to sustain chemotherapy-related
toxicity. However, mitotane remained the backbone of therapy because the duration of treatment
was prolonged till patient death in most cases while different lines of treatment (cytotoxic drugs,
loco-regional treatments) were superimposed during the disease course. The practice of continuing
mitotane indefinitely, despite ACC progression, has been recently criticized [20], although we lack
clear rules for mitotane discontinuation [2].
A small subset of our patients were treated with mitotane without any other additional systemic
treatment. Interestingly, these patients had a more favorable outcome, and this likely represents
a selection bias because more aggressive tumors usually undergo multiple lines of treatment. The
inclusion of this patient cohort with less aggressive ACC is one of the factors that may explain the
long OS observed in the present study. Not surprisingly, higher mitotane concentrations were attained
in such patients since the combination with cytotoxic agents increases toxicity and makes it difficult
to give high doses of mitotane. In a small prospective trial of 12 weeks, including 40 mitotane-naïve
patients with metastatic ACC, assigned to a low- or high-dose mitotane regimen, the high-dose regimen
resulted in higher exposure to mitotane in patients not receiving concomitant chemotherapy, despite
cumulative doses not being significantly different among the subgroups [21].
A recent retrospective study including 127 patients with advanced ACC treated with mitotane
monotherapy introduced the concept that either a low tumor burden (<10 tumor lesions) or longer
recurrence-free survival (RFS) after primary surgery (≥360 days) are characteristics predicting treatment
efficacy [6]. We did not find any difference on tumor burden, expressed as the number of metastatic
organs, although we did not capture data on the number of metastatic lesions. However, RFS was
almost double in the cohort of patients treated with mitotane alone, despite levels of significance not
being reached for the low numbers, thus confirming the validity of the concept that tumors with lower
proliferation capability (heralded by prolonged RFS) are best suited for mitotane monotherapy.
An interesting finding of the present study is that the TTR of plasma mitotane concentrations
is able to predict survival, with a higher value associated with longer survival. This was consistent
with the previous literature, which established the therapeutic value of mitotane concentrations of
14–20 mg/L [4–8,22]. We adopted the TTR using a concept analogous to warfarin treatment [9] that we
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recently used in a study on adjuvant mitotane treatment [23]. In that study, we found that a higher TTR
was associated with a reduced risk of ACC recurrence [23]. In the present study, we found that patients
with ACC progression had a lower time in the target range than patients experiencing clinical benefit
from first-line treatment, and in multivariable analysis, TTR was a predictor of OS. This confirms that
TTR could represent a valuable measure of mitotane efficacy also in advanced ACC.
In our study, the overall activity of first-line treatment was limited, with a low number of objective
responses (13.7%) and of patients experiencing clinical benefit (23.7%), with no observed difference
between patients treated with mitotane + chemotherapy or mitotane monotherapy. We observed
that a lower number of patients with advanced ACC benefitted from first-line treatment, either
mitotane + chemotherapy or mitotane monotherapy, compared to the FIRM-ACT study and two recent
retrospective studies [3,6,22]. However, the present study was not specifically designed to analyze the
efficacy of treatment.
Strengths of the present study are the large data set of patients with available clinical information
and data on mitotane measurement, considering the rarity of ACC and the high mortality in the setting
of advanced disease. On the other hand, we are aware that our analysis is limited by its retrospective
and multicenter nature. Therefore, we did not evaluate progression-free survival, which is heavily
influenced by variable schedules of restaging in retrospective studies, and we only considered overall
survival, taking into account that the inclusion criteria produced an immortal time of three months,
and that we included patients with at least three mitotane measurements.
4. Materials and Methods
For this study, we invited 13 tertiary centers for the care of ACC patients in Italy. Twelve centers
accepted the invitation to participate in the survey, providing clinical, pathological, and biochemical
data of all patients with advanced ACC who had been proactively followed at the center and treated
with mitotane. We retrieved the data of patients who were treated from July 2005 to March 2017.
Follow up for this study was closed on 1 November 2019. The institutional ethics committee of all
centers approved the study, and all patients signed written informed consent (Ethical Committee of
AOU San Luigi Gonzaga (Orbassano, Turin, Italy) and of AA.SS.LL. TO3–TO4–TO5 based at AOU
San Luigi Gonzaga (Orbassano, Turin, Italy). Number of dossier 36/2012, validate on the session of
22 February 2012).
Inclusion criteria of the study were as follows: Age ≥ 18 years, pathologically confirmed diagnosis
of ACC, availability of computed tomography (CT) or magnetic resonance imaging (MRI) scans,
complete follow-up information, treatment with mitotane (all patients received the same mitotane
formulation, Lysodren® 500 mg tablets) for ≥ 3 months, and with > 3 measurements of plasma
mitotane concentrations reported on the Lysosafe Online® database. Exclusion criteria were as follows:
Incomplete tumor staging, history of other previous or concomitant malignancies, and incomplete
follow-up information.
Patients’ charts were reviewed and the following information was retrieved for the study: Gender,
date of birth, date of diagnosis, hormone secretion and tumor stage at diagnosis, pathology report, date
of recurrence (in case of previous adjuvant treatment), date of start of palliative treatment, hormone
secretion and ACC stage at start of palliative treatment, number and type of organs/systems with
metastasis at start of palliative treatment, and last follow-up or death. Date of diagnosis was defined
as the date of surgery or the date of biopsy for tumors not operated on. Biochemical confirmation
of hormone excess was requested to categorize an ACC as hormone secreting. Tumor stage was
established according to the ENSAT classification (I and II, confined tumor; III, positive lymph nodes
or infiltrating neighboring organs/veins without distant metastases; IV, distant metastases) [24]. Date
of recurrence was defined as the date of radiological evidence of a new lesion. A questionnaire was
sent to the participating centers to retrieve the information requested for the study; moreover, centers
were asked about indications, timing of initiation and discontinuation, reasons for discontinuation
of mitotane treatment, and follow-up modality. Duration of treatment was calculated from the date
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of the initiation of mitotane therapy until the discontinuation of treatment, or the end of follow-up,
whichever occurred first. Treatment response was evaluated according to routine radiologic assessment
and qualified patients were classified on the basis of their best response to the first line of treatment
using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 [10]: Complete response (CR), partial
response (PR), stable disease (SD), and progressive disease (PD). We stratified patients in two groups:
The first group includeed patients with clinical benefit (CR, PR, SD) vs. patients with progression (PD).
For the analysis of plasma mitotane concentrations, we calculated the time in target range (TTR),
defined as the number of months in which mitotane concentrations were ≥14 mg/L, a value considered
as the lower limit of the target range [5,6,8], for all patients. Based on the concept of the “time in
therapeutic range” used for monitoring warfarin therapy [9], we assumed that a linear relationship
existed between consecutive values when a measurement was not available.
Mitotane concentrations were retrieved from the Lysosafe Online® database, available at
www.lysosafe.com. Lysosafe Online® is a login-protected website that stores mitotane plasma
concentrations of patients treated by physicians who have registered with the Lysosafe® service,
a free-of-charge service of the measurement of plasma mitotane concentrations in ACC patients offered
by HRA Pharma to European prescribers since 2005 and associated with the use of Lysodren®. Samples
were collected at the centers, sent to a centralized laboratory, extracted by precipitation with ethanol,
and tested by a standardized gas chromatography/mass spectrometry method. Plasma mitotane
values of any patient were available for the treating physician on www.lysosafe.com, in a historical
and graphic plot that matches mitotane levels with the relative Lysodren® dose. Patient data are
anonymous during the whole process since patients are recorded using an acronym and their date
of birth.
All communication concerning the study between centers was by email, and a meeting was
organized to make the process of data capture more homogeneous.
Statistical Analysis
Categorical data are presented as counts and percentages. Continuous data are presented as
medians and interquartile ranges (IQR). Differences in categorical variables were analyzed by means
of the chi-squared test or Fisher test as appropriate, while differences in continuous variables were
analyzed by the Mann–Whitney U test. The survival curves were estimated with the Kaplan–Meyer
product limit method. RFS was calculated from the time of initial surgery to the first radiological
evidence of recurrence. OS was calculated from the start of palliative treatment to the date of death.
Patients who did not experience either of those events (recurrence or death) were censored at the
date of the last follow-up visit for the specific survival analysis. Cox proportional hazards regression
models were fitted to determine prognostic factors on OS. The following potential predictive factors for
OS were investigated: Patient sex, age, and hormone secretion at the starting of palliative treatment,
length of RFS (0 for de novo stage IV), the number of organs with metastasis at the start of palliative
treatment, the time elapsed to get the first plasma mitotane level at target during palliative treatment,
the peak of mitotane concentrations during palliative treatment, and response to treatment.
Since variable selection based on univariate analysis cannot properly control for a potential
spurious relationship [25], the best subset regression approach was chosen for building a multivariate
model [26]. According to this approach, all the possible combinations of the candidate variables were
considered, then model selection was based on the Akaike information criteria method [27].
All reported p values are two-sided. The p values less than 0.05 were considered as statistically
significant. The statistical analyses were performed with Statistica (StatSoft) (Dell Software, Round
Rock, TX, USA) and R version 3.5.1 (R Core Team, St. Louis, MO, USA).
5. Conclusions
In reference centers in Italy, the two options for treatment of advanced ACC (mitotane alone or
plus chemotherapy) were almost equally chosen, but mitotane remained the backbone of therapy
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because the duration of treatment was prolonged till patient death in most cases. The observation
that the TTR of plasma mitotane concentrations has prognostic implications is novel and supports the
importance of mitotane monitoring and the value of the concept of a therapeutic window for mitotane.
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